Genital Herpes Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical and Non-Clinical Trials Evaluation, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

As per DelveInsight's assessment, about 26+ key pharma and biotech companies are working on 28+ pipeline drugs in the Genital Herpes therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Genital Herpes Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Genital Herpes Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Genital Herpes Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing therapies in the Genital Herpes Market.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Genital Herpes treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Genital Herpes market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Learn More about the Clinical and Commercial Development Activities in the Genital Herpes Therapeutics Domain:
https://www.delveinsight.com/report-store/genital-herpes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
Genital Herpes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Genital Herpes Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type
Genital Herpes Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/genital-herpes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Genital Herpes Therapeutics Analysis
Several major pharma and biotech giants are developing therapies for Genital Herpes. Currently, AiCuris is leading the therapeutics market with its Genital Herpes drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Genital Herpes Therapeutics Market Include:
Acoricus, Admedus Immunotherapies, Agenus, AiCuris Assembly Biosciences, Auritec Pharmaceuticals, BioNTech, BlueWillow Biologics, Brandenburg Antiinfektiva GmbH, Fresh Tracks Therapeutics, Genocea Biosciences, GlaxoSmithKline, GSK Pharmaceuticals, Heidelbergmmuno Therapeutics, Immune System Regulation, JN-International Medical Corporation, Moderna Therapeutics, Nanoviricides, Sanofi, Shulov Institute for Science LTD, Squarex Pharma, Starpharma, United BioPharma, Vaccibody, Vaxxit, X-Vax Technology, and others.

Genital Herpes Emerging and Marketed Drugs Covered in the Report Include:
• Biological: HSV 2 Formulations: Sanofi
• HDIT101: HeidelbergmmunoTherapeutics
• HSV type 2 vaccines - Vaccibody
• NE HSV-2 vaccine: BlueWillow Biologics
• Pritelivir - Acoricus
• SQX-770- Squarex Pharma
• UB 621: United BioPharma
• Zovirax- GSK Pharmaceuticals
And Many More

Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/genital-herpes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Genital Herpes Current Treatment Patterns
4. Genital Herpes - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Genital Herpes Late-Stage Products (Phase-III)
7. Genital Herpes Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Genital Herpes Discontinued Products
13. Genital Herpes Product Profiles
14. Genital Herpes Key Companies
15. Genital Herpes Key Products
16. Dormant and Discontinued Products
17. Genital Herpes Unmet Needs
18. Genital Herpes Future Perspectives
19. Genital Herpes Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/genital-herpes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.